| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CTRV.2008.02.004 |
| P698 | PubMed publication ID | 18423992 |
| P50 | author | Ingunn Holen | Q58218901 |
| P2093 | author name string | R E Coleman | |
| M C Winter | |||
| P433 | issue | 5 | |
| P304 | page(s) | 453-475 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Exploring the anti-tumour activity of bisphosphonates in early breast cancer | |
| P478 | volume | 34 |
| Q34541581 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study |
| Q39621014 | A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer |
| Q94475957 | AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway |
| Q54373964 | Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). |
| Q92910688 | Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) |
| Q35095543 | Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients |
| Q35066934 | Adjuvant bisphosphonates in breast cancer treatment |
| Q35076216 | Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy? |
| Q26781435 | Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? |
| Q59616788 | Adjuvant endocrine therapy in premenopausal women with breast cancer |
| Q42603658 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. |
| Q37357660 | Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials |
| Q37610799 | Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies |
| Q34130512 | An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer |
| Q36759195 | Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate |
| Q37794160 | Anticancer Properties of Zoledronic Acid |
| Q37812731 | Antitumor Effects and Anticancer Applications of Bisphosphonates |
| Q36207662 | Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting |
| Q34032539 | Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy |
| Q35596736 | Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer |
| Q92604203 | Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women |
| Q26795493 | Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence |
| Q33708123 | Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk |
| Q36299278 | Bisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis |
| Q21132670 | Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis |
| Q36963360 | Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate! |
| Q36491642 | Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting. |
| Q35095558 | Breast Cancer: Rank Ligand Inhibition. |
| Q35496778 | Breast cancer medications and vision: effects of treatments for early-stage disease |
| Q35750453 | Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? |
| Q34147910 | Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways |
| Q33531646 | Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction |
| Q36240183 | Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model. |
| Q64275265 | Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study |
| Q37777391 | Current and emerging concepts in tumour metastasis |
| Q44635510 | Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. |
| Q37986124 | Denosumab for treatment of breast cancer bone metastases and beyond |
| Q36491529 | Does estrogen play a role in response to adjuvant bone-targeted therapies? |
| Q36491459 | Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort |
| Q34015944 | Effect of bisphosphonates on pain and quality of life in patients with bone metastases |
| Q39899122 | Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. |
| Q37055591 | Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials |
| Q34581699 | Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol |
| Q87247237 | Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study |
| Q43073125 | Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. |
| Q34075052 | Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. |
| Q42363605 | Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. |
| Q36524247 | Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid |
| Q27022446 | Exposure to bisphosphonates and risk of colorectal cancer |
| Q45075711 | Exposure to bisphosphonates and risk of colorectal cancer: a population-based nested case-control study |
| Q36804951 | First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial |
| Q50788126 | Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. |
| Q36283738 | Importance of antiresorptive therapies for patients with bone metastases from solid tumors |
| Q33587199 | Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial |
| Q39781826 | Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells |
| Q37823605 | Managing bone health with zoledronic acid: a review of randomized clinical study results |
| Q98465934 | Molecular mechanisms and clinical management of cancer bone metastasis |
| Q35987443 | Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment |
| Q35667692 | Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium |
| Q37917774 | New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response |
| Q37923744 | New role for an established drug? Bisphosphonates as potential anticancer agents |
| Q33415020 | New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases. |
| Q37355487 | Optimal management of bone metastases in breast cancer patients |
| Q35583788 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. |
| Q55237144 | Oral bisphosphonate use and lung cancer incidence among postmenopausal women. |
| Q34287614 | Osteonecrosis of the jaw and bevacizumab therapy |
| Q36702139 | Pathways to breast cancer recurrence. |
| Q36945036 | Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice |
| Q46949164 | Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis |
| Q38192969 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma |
| Q50952266 | Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. |
| Q33447971 | Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases |
| Q36394320 | Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid |
| Q33926132 | Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors |
| Q38101363 | Safety concerns with the long-term management of osteoporosis |
| Q38751743 | Synthesis and evaluation of alendronate-modified gelatin biopolymer as a novel osteotropic nanocarrier for gene therapy |
| Q40052962 | The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid |
| Q45330835 | The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population |
| Q24597847 | The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer |
| Q36337775 | The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis |
| Q39762559 | The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells |
| Q38791765 | The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. |
| Q34524201 | The pre-metastatic niche: is metastasis random? |
| Q37944154 | The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer |
| Q34145863 | The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives |
| Q35911516 | Toxicity of a dental adhesive compared with ionizing radiation and zoledronic acid. |
| Q35667196 | Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice |
| Q34896573 | Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene |
| Q37401841 | Treatment options for breast cancer and bone metastases |
| Q37807047 | Understanding and Optimizing Bone Health in Breast Cancer |
| Q37794991 | Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. |
| Q34877539 | Use of bisphosphonates and reduced risk of colorectal cancer |
| Q37684242 | Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. |
| Q39188074 | Zoledronic acid and radiation: toxicity, synergy or radiosensitization? |
| Q53229533 | Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach. |
| Q43250823 | Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice |
| Q35534524 | Zoledronic acid in breast cancer: latest findings and interpretations |
| Q37960410 | Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? |
| Q44240872 | Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells |
| Q37294327 | Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. |
| Q37828494 | Zoledronic acid use in cancer patients: more than just supportive care? |
| Q37354133 | Zoledronic acid: a review of its use in breast cancer |
| Q83277811 | [Bone metastasis in prostate cancer] |
Search more.